3 hours ago
1
- The US FDA approved Gazyva (obinutuzumab), a lupus nephritis treatment from Roche-owned (OTCQX:RHHBY) Genentech.
- Gazyva is given via infusion four times in the first year, followed by twice a year after that.
- In a phase 3 study, 46.4% of patients on Gazyva
English (US) ·